Skip to main content
PIRAMAL PHARMA LIMITED logo

PIRAMAL PHARMA LIMITED — Investor Relations & Filings

Ticker · PPLPHARMA ISIN · INE0DK501011 LEI · 3358006D6AL7PZ4U9T51 BSE.NS Manufacturing
Open in API
Filings indexed 367 across all filing types
Latest filing 2023-05-24 Earnings Release
Country IN India
Listing BSE.NS PPLPHARMA

About PIRAMAL PHARMA LIMITED

https://www.piramalpharma.com/

Piramal Pharma Limited provides a broad range of products and services across the drug lifecycle through three main business segments: Piramal Pharma Solutions, Piramal Critical Care, and Consumer Healthcare. Piramal Pharma Solutions operates as an integrated Contract Development and Manufacturing Organization (CDMO), offering end-to-end services from drug discovery and development to commercial manufacturing of APIs and formulations. Piramal Critical Care focuses on complex hospital generics, holding a significant global market share in inhalation anesthetics, including Sevoflurane and Isoflurane, as well as injectable anesthesia and pain management therapies. The Consumer Healthcare division manages a diverse portfolio of over-the-counter brands such as Saridon, Lacto Calamine, and Tetmosol. The company leverages an extensive global manufacturing network to deliver specialized healthcare solutions worldwide.

Recent filings

Filing Released Lang Actions
Press Release
Earnings Release Classification · 95% confidence The document is a press release dated May 24, 2023, announcing the audited financial results (standalone and consolidated) for the quarter and year ended March 31, 2023. It includes detailed financial highlights, profit and loss statements, balance sheet data, and business segment performance. The document also contains a notice about an upcoming earnings conference call to discuss these results. The content is comprehensive and includes actual financial data and analysis for the full fiscal year and quarter, not just a summary or announcement of a report. Therefore, it fits the definition of an Earnings Release (ER), which is the initial announcement of quarterly/periodical financial results with key highlights. It is not a full Annual Report (10-K) as it lacks the extensive narrative and disclosures typical of such reports, nor is it an Interim/Quarterly Report (IR) since it is a press release format. The presence of a conference call announcement further supports classification as an Earnings Release. FY 2023
2023-05-24 English
Investor Presentation
Annual Report Classification · 95% confidence The document is a press release dated May 24, 2023, announcing the audited financial results (standalone and consolidated) for the quarter and year ended March 31, 2023. It includes detailed financial highlights, profit and loss statements, balance sheet data, and business segment performance. The document also contains an investor presentation and announces a conference call to discuss these results. The content is comprehensive, with actual financial data and analysis for the full fiscal year, indicating it is a full annual financial report rather than a brief earnings release or a simple announcement. The presence of detailed financial statements and management commentary confirms it is an Annual Report type document. Therefore, the appropriate classification is Annual Report (10-K). FY 2023
2023-05-24 English
Financial Result Updates
Annual Report Classification · 95% confidence The document is a detailed communication from Piramal Pharma Limited dated 24th May 2023, reporting the outcome of a Board Meeting where the Audited Financial Results (Standalone & Consolidated) for the quarter and financial year ended 31st March 2023 were approved. It includes comprehensive financial data such as income statements, balance sheets, cash flow statements, notes, and auditor's reports. The document references compliance with SEBI Listing Regulations and includes statutory auditor's reports and declarations. The length is substantial (15,000 characters), and it contains actual financial statements and analysis, not just an announcement or certification. Therefore, this document is the full Annual Report or equivalent annual audited financial results filing, which corresponds to the Annual Report category (10-K). FY 2023
2023-05-24 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement from Piramal Pharma Limited dated 24th May 2023, reporting the outcome of a Board Meeting where the Audited Financial Results (Standalone & Consolidated) for the quarter and financial year ended 31st March 2023 were approved. It includes comprehensive financial data such as income statements, balance sheets, cash flow statements, and notes. The document references compliance with SEBI Listing Regulations and includes the statutory auditor's report with an unmodified opinion. The length of the document (15,000 characters) and the presence of full financial statements and audit opinions indicate this is the actual financial report rather than a brief announcement or certification. The content matches the characteristics of an Interim / Quarterly Report (IR) because it covers quarterly and annual audited financial results, including detailed financial statements and notes, but it is not a full annual report (10-K) which would be more extensive and cover broader company activities. Therefore, the document is best classified as an Interim / Quarterly Report (IR). FY 2023
2023-05-24 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is an intimation of a conference call scheduled to discuss Q4 and FY2023 earnings results of Piramal Pharma Limited. It is addressed to stock exchanges and investors, providing details about the call timing, dial-in numbers, and registration link. The document does not contain any financial statements, analysis, or detailed results itself, but rather announces the upcoming earnings call event. According to the classification rules, such announcements of conference calls are classified as Call Transcript (CT) only if they contain the full transcript. Since this document is only an announcement of the call, it fits best under Regulatory Filings (RNS) as a general regulatory announcement. The document length is short (4106 characters), and it does not contain the actual earnings release or transcript, so it is not an Earnings Release (ER) or Call Transcript (CT). Therefore, the appropriate classification is Regulatory Filings (RNS) with high confidence.
2023-05-23 English
Updates
Regulatory Filings Classification · 95% confidence The document is a short disclosure letter addressed to stock exchanges regarding the completion of a US FDA inspection at a company facility. It mentions compliance and inspection results but contains no financial data, no detailed report, or financial statements. The document is brief (1331 characters) and serves as a regulatory announcement under SEBI regulations. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is not a certification letter but a regulatory disclosure. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2023-05-19 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.